<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02033278</url>
  </required_header>
  <id_info>
    <org_study_id>CMMo/MD/2013</org_study_id>
    <nct_id>NCT02033278</nct_id>
  </id_info>
  <brief_title>Infusion Intracoronary of Mononuclear Autologous Adult no Expanded Stem Cells of Bone Marrow on Functional Recovery in Patients With Idiopathic Dilated Cardiomyopathy and Heart Failure.</brief_title>
  <official_title>Multicenter Phase IIb Clinical Trial, Double-blind, Randomized, Controlled Placebo for to Assess the Efficacy of Intracoronary Infusion of Autologous Adult Stem Cells Mononuclear Marrow Unexpanded on Functional Recovery in Patients With Idiopathic Dilated Cardiomyopathy and Heart Failure.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Iniciativa Andaluza en Terapias Avanzadas</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Clinical trial phase IIb, double-blind, randomized, controlled with placebo. There is
      sufficient preliminary evidence to consider intracoronary injection of bone marrow progenitor
      cells as a viable, safe and beneficial treatment in patients with dilated cardiomyopathy,
      although the biological mechanism of action of bone marrow cells in the myocardium is not
      known. In this project we propose to investigate comparatively and from a biological and
      clinical point of view the applicability of regenerative therapy with autologous bone marrow
      cells in patients with dilated cardiomyopathy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study population correspond to male and female patients with idiopathic dilated
      cardiomyopathy.

      51 patients diagnosed with this disease are included. After inclusion, will proceed to the
      random allocation to study group or control group in a 2:1 ratio, 34 patients in the
      treatment group and 17 in the control group.

      The total duration is expected to be 48 months: The inclusion period is 24 months and each
      patient assigned to the experimental group will be followed for 24 months, whereas that one
      ramdomized to the control group, will have a folow-up of 12 months. Upon completion there of,
      the patients will be followed in routine clinical practice.

      This is a double blind study, in which all patients will perform the bone marrow harvesting.

      All patients will receive the best medical treatment individualized (ACEIs or Angiotensin II
      receptor blocker, beta-blockers, diuretics and eplerenone) for at least 6 months prior to
      their participation in the clinical trial, so that the situation is stable and
      pharmacological basal condition is the same for everyone.

      The bone marrow cells of patients assigned to placebo group will be cryopreserved, and once
      the trial is completed, the blind will be opened and all the patients who had been randomized
      to the control group, may be processed by the route of compassionate use with their own
      mononuclear bone marrow cells previously frozen.

      The patients who are randomized to experimental group will be treated by the conventional
      treatment + infusion of autologous mononuclear bone marrow cells not expanded whereas the
      patients who are randomized to control group will be treated by the conventional treatment +
      infusion of placebo.

      The main objective is to assess comparative the efficacy of intracoronary injection of bone
      marrow stem cells autologous to improve ventricular function in patients with idiopathic
      dilated cardiomyopathy who receive conventional medical treatment, compared with a control
      group who receive a infusion of placebo and conventional medical treatment. The improvement
      in ventricular function assessed by changes in angiographically determined ejection fraction.

      Secondary objectives of the study are:

      - To analyze the predictors of good clinical response, functional and biological treatment
      with adult stem cells autologous mononuclear bone marrow not expanded in terms of functional
      recovery.

      The following parameters were evaluated: Functional class (NYHA), Natriuretic peptide B,
      Stress test (exercise time), Echocardiographic parameters of ventricular function, for
      example LVEF (%), TDV (ml), TSV (ml) and TAPSE (ms) and Biological parameters of cellular
      functionality, for example CD133 +, CD34 +, CD34 +/CD177 + and CD34 +/CD38- (in %).

      - To determine, in the light of the obtained results, the application protocol suitable cell
      therapy for the treatment of dilated cardiomyopathy.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 6, 2014</start_date>
  <completion_date type="Anticipated">February 2022</completion_date>
  <primary_completion_date type="Anticipated">February 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in ventricular function measured angiographically.</measure>
    <time_frame>24 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Degree of clinical improvement based on the absence of major cardiac events (MACE) during follow-up.</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical and analytical progress (NYHA grade &amp; BNP)</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of evolution since diagnosis of idiopathic dilated cardiomyopathy prior to study entry.</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional recovery as measured with ergometry</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Echocardiography and Electrocardiography variables</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">51</enrollment>
  <condition>Idiopathic Dilated Cardiomyopathy</condition>
  <arm_group>
    <arm_group_label>Infusion of autologous mononuclear bone marrow cells</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Infusion of autologous mononuclear bone marrow cells plus conventional medical treatment (as indicated by clinician)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo infusion</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo infusion plus conventional medical treatment (as indicated by clinician)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Infusion of autologous mononuclear bone marrow cells</intervention_name>
    <description>Infusion of autologous mononuclear bone marrow cells plus conventional medical treatment (as indicated by clinician)</description>
    <arm_group_label>Infusion of autologous mononuclear bone marrow cells</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo infusion</intervention_name>
    <description>Placebo infusion plus conventional medical treatment (as indicated by clinician)</description>
    <arm_group_label>Placebo infusion</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients of both sexes and ages between 18 and 70 years.

          2. Patients diagnosed with dilated cardiomyopathy established by echocardiography.

          3. Minimum evolution since diagnosis of 6 months.

          4. Absence of coronary injury tested with multislice CT and/or hemodynamic study
             performed after study entry, or within the previous 36 months (or before in specific
             low risk clinical profiles) if no angina symptomatology is present.

          5. Patients receiving optimized medical therapy for at least 6 months prior to enrollment
             (individually adjusted according to functional status).

          6. Ejection fraction of the left ventricle &lt;40% or ejection fraction of the left
             ventricle 40% -50% if left ventricular tele-diastolic volume is &gt; 110 ml/m2.

          7. Presence of sinus rhythm.

          8. Writen informed consent for participation in the trial.

          9. Normal laboratory parameters, defined by: Leukocytes ≥ 3000; Neutrophils ≥ 1500;
             Platelets ≥ 100,000; Aspartate aminotransferase / Alanine aminotransferase ≤ 2.5
             standard range institution; Creatinine ≤ 2.5 mg / dL; Haemoglobin &gt; 9 g/dL

         10. Women of childbearing potential must have negative results on a pregnancy test and
             agree to use medically approved methods of contraception thoughout follow up.

        Exclusion Criteria:

          1. Secondary Dilated cardiomyopathy.

          2. Recent history of myocarditis (&lt; 6 months prior to study entry).

          3. Patients amenable to receive cardiac resynchronization therapy

          4. Patients in active waiting list for heart transplantation.

          5. Coexistence of other serious systemic diseases.

          6. Coexistence of any type of blood disease

          7. Pregnant or breastfeeding women; or women of childbearing potential not comminting to
             use effective contraception.

          8. Patients who are currently participating, or have completed their participation in a
             clinical trial within the last 3 months. Patients who have participated in any
             advanced therapies clinical trial any time previously.

          9. Patients with malignant or pre-malignant tumors.

         10. Positive serology for hepatitis B virus, hepatitis C virus or human immunodeficiency
             virus.

         11. Use of any protocolo prohibited medication. A wash-out period of 2 months can be
             considered for inclusion in the trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Miguel Romero Moreno, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitario Reina Sofía</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Manuel Sobrino Marquez, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospitales Universitarios Virgen del Rocío</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Luis A Iñigo García, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Costa del Sol</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ricardo Zayas Rueda, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitario Puerta del Mar</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Manuel De Mora Martín, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Regional U. Carlos Haya</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Silvia López Fernández, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Virgen de las Nieves</affiliation>
  </overall_official>
  <overall_official>
    <last_name>José Francisco Díaz Fernández, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitario Juan Ramón Jimenez</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jesús Oneto Otero, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital de Jerez</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Rafael Ruiz Salmerón, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitario Virgen Macarena</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Juliana Martínez-Atienza</last_name>
    <phone>0034 955048278</phone>
    <email>juliana.martinez.ext@juntadeanlacia.es</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital Universitario Puerta del Mar</name>
      <address>
        <city>Cádiz</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ricardo Zayas Rueda, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Ricardo Zayas Rueda, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopistal Universitario Reina Sofía</name>
      <address>
        <city>Córdoba</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Miguel Romero Moreno, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Miguel Romero Moreno, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen de las Nieves</name>
      <address>
        <city>Granada</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Silvia López Fernández</last_name>
    </contact>
    <investigator>
      <last_name>Silvia López Fernández</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Juan Ramón Jimenez</name>
      <address>
        <city>Huelva</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jose F Diaz Fernández</last_name>
    </contact>
    <investigator>
      <last_name>Jose F Diaz Fernández, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital de Jerez</name>
      <address>
        <city>Jerez De La Frontera</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jesús Oneto Otero, MD</last_name>
    </contact>
    <investigator>
      <last_name>Jesus Oneto Otero, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Costa del Sol</name>
      <address>
        <city>Marbella</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luis A Iñigo García, MD</last_name>
    </contact>
    <investigator>
      <last_name>Luis A Iñigo García, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Regional U. Carlos Haya</name>
      <address>
        <city>Málaga</city>
        <zip>29014</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Manuel De Mora Martín, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Manuel De Mora Martín, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen del Rocío</name>
      <address>
        <city>Sevilla</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Manuel Sobrino Marquez, MD</last_name>
    </contact>
    <investigator>
      <last_name>Manuel Sobrino Marquez</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen Macarena</name>
      <address>
        <city>Sevilla</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rafael Ruiz Salmerón, MD</last_name>
    </contact>
    <investigator>
      <last_name>Rafael Ruiz Salmeron, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <link>
    <url>http://www.juntadeandalucia.es/terapiasavanzadas/</url>
  </link>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 9, 2014</study_first_submitted>
  <study_first_submitted_qc>January 9, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 10, 2014</study_first_posted>
  <last_update_submitted>March 25, 2018</last_update_submitted>
  <last_update_submitted_qc>March 25, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 27, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Cardiomyopathies</mesh_term>
    <mesh_term>Cardiomyopathy, Dilated</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

